Global Theranostics Market - 2023-2030

Global Theranostics Market - 2023-2030

The global theranostics market reached US$ 1.8 billion in 2022 and is expected to witness lucrative growth by reaching up to US$ 4.2 billion by 2030. The global theranostics market is to exhibit a CAGR of 11.3% during the forecast period (2023-2030).

Theranostics is a combination of the terms therapeutics and diagnostics. Theranostics is the term used to describe the combination of using one radioactive drug to identify (diagnose) and a second radioactive drug to deliver therapy to treat the main tumor and any metastatic tumors. These tests are mainly used for various forms of cancers. The key concern in therapeutics involves patient-centric care with the help of a more personalized and precise approach.

Recent trends in the global theranostics market include the widespread adoption of nanomedicines for their imaging capabilities and their integration into a single entity known as nanotheranostics, which combines diagnosis and drug therapy. Additionally, there is a growing interest in using aggregation-induced emissive luminogens for bacterial theranostics.

The market is witnessing rising investment and collaborations among pharmaceutical companies, research institutions, and healthcare providers. This is driven by the increasing demand for theranostics, which offer personalized and targeted treatments. Furthermore, ongoing research endeavors in the field of theranostics, a rise in the number of clinical trials, and the increasing number of conferences aimed at raising awareness and promoting advancements are anticipated to be key driving factors throughout the forecast period.

Market Dynamics
Increasing Research Conferences in Radionuclide Theranostics for the Management of Cancer are to Drive Global Theranostics Market Growth

According to Gordon Research Conference 2022, it will explore the latest advancements and impact of Radionuclide Theranostics in the management of cancer patients. It aims to facilitate formal and informal interactions and collaborations among a distinguished group of speakers, including scientists, physicians, and experts from various sectors such as academia, private practice, and industry. The primary scientific objective of the conference is to address the challenges associated with radionuclide theranostics and encourage significant breakthroughs in cancer research.

The unique format of the conference, characterized by its small size, secluded setting, unpublished data, and ample time for discussion, provides an exceptional opportunity for meaningful interactions and collaborations that are likely to have a substantial and enduring impact on the field. This gathering is particularly significant as precision oncology utilizing radionuclide-based imaging and therapy is experiencing a transformative phase of innovation and remarkable growth.

It offers the potential for more precise diagnostics and personalized and effective anti-tumor treatments than ever before. Moreover, this is evident from the increasing participation of major pharmaceutical companies and the emergence of over 50 new players in the field of radiotheranostics.

Furthermore, the number of clinical trials utilizing beta, alpha, or gamma-emitting radionuclides in cancer treatment is rapidly expanding. The timing of this conference is crucial, as it coincides with the pivotal moment when radionuclide-based precision oncology is poised for significant advancements, signifying a paradigm shift in the field and unprecedented progress. Thus, owing to the above factors, the market is to drive over the forecast period.

Increasing FDA Approvals in Cancer are to Drive Global Theranostics Market Growth

On November 29, 2022, Clarity Pharmaceuticals received approval from the FDA to conduct clinical trials with SAR-Bombesin, a theranostic agent, for the treatment of prostate cancer. Prostate cancer ranks as the fifth leading cause of cancer-related deaths worldwide and is the second most commonly diagnosed cancer in men. In the United States alone, approximately 268,490 cases of prostate cancer are reported annually, resulting in about 34,500 deaths, according to the NCI.

SAR-Bombesin is a radiopharmaceutical designed to target specific cell surface receptors present in various types of cancer. The press release highlights that gastrin-releasing peptide receptors (GRPr) can be found in 75-100% of prostate cancers.

The SAR-Bombesin compound offers multiple benefits. Its SAR component, also known as sarcophagine, acts as a chelator that securely encapsulates copper isotopes, preventing any leakage into the body. The company states SAR-Bombesin is a Targeted Copper Theranostic (TCT) that can utilize copper-64 isotopes (Cu-64 or 64Cu) for imaging purposes and copper-67 isotopes (Cu-67 or 67Cu) for therapeutic applications.

Similarly, on March 23, 2022, Novartis received FDA approval for PluvictoTM (lutetium Lu 177 vipivotide tetraxetan), previously known as 177Lu-PSMA-617. This approval allows Pluvicto to be used in the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) who have prostate-specific membrane antigen-positive (PSMA-positive) tumors that have spread to other parts of the body. These patients have already undergone other anticancer treatments such as androgen receptor pathway inhibition and taxane-based chemotherapy.

Additionally, the FDA has approved Locametz (kit for the preparation of gallium Ga 68 gozetotide injection). After radiolabeling, this imaging agent can be used in adult patients with mCRPC to identify PSMA-positive lesions through positron emission tomography (PET) scans.

By using Gallium-68 labeled Locametz, physicians can detect tumor lesions expressing the PSMA biomarker and determine the spread of tumors in the body, including soft tissue, lymph nodes, or bone. This helps identify patients eligible for targeted treatment with Pluvicto. PSMA is highly expressed in over 80 percent of patients with prostate cancer, making it a crucial biomarker for assessing the progression of metastatic prostate cancer.

High Cost of Theranostics is to Hamper Global Theranostics Market Growth
The field of theranostics, which utilizes radiopharmaceuticals, holds great promise for improving cancer diagnosis and treatment. However, some of the most effective theranostic agents rely on rare isotopes that are challenging to obtain and costly to convert into drugs capable of targeting and eliminating cancer cells. While advancements in cancer care are shortly, they will inevitably come with a high price tag.

For instance, the cost of Lutetium-177 therapy for cancer diagnosis varies depending on the country, hospital, and treating doctor. The average cost of Lutetium-177 therapy is around $10,000 per course, and a patient may undergo three to four courses.

Similarly, in India, the estimated cost of Lu177 PSMA Therapy usually starts at $5000 and may go up to $6000. Also, in Germany, the cost of PSMA therapy with Lutetium 177 in specialized hospitals ranges between 8000-16,000 euros, which covers the cost of the initial clinical and laboratory examination, the PSMA therapy itself, the follow-up examinations, and the hospital stay. Thus, owing to the above factors, the market is to hamper over the forecast period.

COVID-19 Impact Analysis
The theranostics market is to face initial challenges and decline during the forecast period due to the impact of the COVID-19 outbreak. Nationwide lockdowns and restrictions have led to disrupted diagnostic services and canceled procedures, affecting the demand for theranostics.

The pandemic has particularly affected the care of patients with oncology and cardiovascular diseases, as they are at a higher risk of severe illness due to their age and comorbidities. The extent of the outbreak and the restrictions imposed vary across regions, influencing individuals with chronic diseases differently.

In countries like Germany, efforts were made to prevent strain on the healthcare system, but public lockdowns and limited access to non-urgent medical services were implemented. The healthcare industry has experienced disruptions in supply chains and demand due to COVID-19.

Theranostics, which can assist in reducing the virulence of infections, including COVID-19, have been impacted as the fear of hospital visits among the public has slowed down the demand for theranostic procedures, which are commonly used in oncology and tumor-related conditions. However, as the pandemic is brought under control and people adapt to the new lifestyle, medical experts have been studying the virus and exploring the use of theranostics in its treatment.

The global impact of the COVID-19 pandemic necessitates the implementation of more effective measures to mitigate the spread of the virus and develop efficient theranostic agents. The high heterogeneity of viruses, including the coronavirus, poses a significant challenge in developing effective antiviral agents. The virus's high mutation rates can negatively impact virus detection, the efficacy of drug and vaccine development, and even lead to drug resistance. However, the field of theranostics offers promising solutions.

Additionally, the use of nanorobots provides real-time protection against viruses, opening up possibilities for significant advancements in theranostics for various diseases, including COVID-19. Furthermore, nanotechnology-based approaches not only revolutionize traditional disinfection procedures but also offer analytical tools for accelerated monitoring of the coronavirus and its associated biomarkers. These approaches can facilitate drug delivery to the respiratory system or other affected organs.

Russia-Ukraine Conflict Analysis
The Russian-Ukraine war has had an impact on various aspects of the global geopolitical landscape, including potential implications for the theranostics market. In the face of political instability, research and development collaborations between institutions in Russia, Ukraine, and other countries may face challenges. Disruptions in scientific collaborations could slow down the progress of theranostic research and hinder the development of new technologies and treatments.

The ongoing conflict may place additional strain on the healthcare systems in both Russia and Ukraine. As resources are redirected towards addressing immediate healthcare needs arising from the conflict, investments, and priorities for theranostics research, infrastructure, and implementation may be affected. Therefore, taking into account the factors mentioned earlier, it can be stated that the theranostics market experienced a moderate impact as a result of the war.

Segment Analysis
The global theranostics market is segmented based on application, radioisotopes, end user, and region.

Oncology from the Application Segment Account for 57.9% of the Market Share Owing to the Increasing Prevalence of Cancer, Growing Theranostics Gordon Research Conferences

According to Pan American Health Organization Report 2023, globally, there were an estimated 20 million new cases of cancer and 10 million deaths from cancer. The cancer burden will increase by approximately 60% over the next two decades, further straining health systems, people, and communities. The predicted global burden will increase to about 30 million new cancer cases by 2040, with the greatest increases occurring in low- and middle-income countries.

In the Americas region the, number of people to be diagnosed with cancer will increase by 57%, to approximately 6.23 million people are predicted to be diagnosed with cancer by 2040, if no further action is taken to prevent and control cancer.

Additionally, On June 23, 2023, Cardinal Health Nuclear & Precision Health Solutions (NPHS) will be showcasing their radiotherapies and theranostics readiness at the annual meeting of the Society of Nuclear Medicine & Molecular Imaging (SNMMI) in booth #2041.

Attendees at the Cardinal Health NPHS booth will have the opportunity to learn about the company's reliable access to radiopharmaceuticals and solutions that contribute to safe, efficient, and high-quality patient care. The booth will feature demonstrations of the Nuctrac theranostic module and offer ""Ask an Expert"" sessions on theranostics and USP <825>, which sets requirements for the preparation, compounding, dispensing, and repackaging of radiopharmaceuticals.

At SNMMI 2023, visitors to Booth #2041 will discover how Cardinal Health NPHS is advancing nuclear medicine through its expertise and comprehensive range of products and services. They are dedicated to improving patient care by enhancing productivity, efficiency, and theranostics practice management solutions. Thus, owing to the above factors, the market segment is to hold the largest market share over the forecast period.

Geographical Analysis
North America Accounted for Approximately 43.9% of the Market Share Owing to the Increasing Prevalence of Cancer, Rising FDA Approvals, and Growing Research in Theranostics

The increasing prevalence of cancer, rising FDA approvals, and growing research in theranostics are some factors due to which the market is to boost in the forecast period. For instance, on March 23, 2022, the U.S. FDA approved 177Lu-PSMA-617, a radiopharmaceutical therapy to treat metastatic castration-resistant prostate cancer (mCRPC). In mCRPC patients treated with 177Lu-PSMA-617, the therapy has been shown to reduce the risk of death by 38% and the risk of progression by 60%. It was developed after years of extensive research.

Furthermore, UChicago Medicine is a leader in the development and administration of theranostic procedures. They are actively researching to expand this promising treatment option for other types of cancer. UChicago Medicine is the only hospital in Illinois to have a medical cyclotron, which is a powerful machine capable of manufacturing new kinds of radiotracers. The research team partners with experts at Argonne National Laboratory, an internationally renowned facility that has provided instrumental research on using radiation to treat cancer.

Sophisticated radiotracers consisting of a biological component engineered to latch on to cancer cells and interchangeable radioactive isotopes that can make those cells visible on a PET scan are providing physicians with more tools to fight certain cancers. Theranostics is a one-two punch against cancer that involves finding cancer cells anywhere in the body and delivering targeted radiation to kill those cells. Thus, owing to the above factors, the North American region is to hold the largest market share over the forecast period.

Competitive Landscape
The major global players in the market include GE Healthcare, Jubilant Pharmova Limited (Jubilant Pharma Limited), Theragnostics Ltd., NuView Life Sciences, Lantheus Holdings, Inc., CapVest Limited (Curium Pharma), Clarity Pharmaceuticals, Cardinal Health, LLC, Advanced Accelerator Applications, and ITM Isotopen Technologien München AG among others.

Why Purchase the Report?
• To visualize the global theranostics market segmentation based on application, radioisotopes, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of theranostics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global theranostics market report would provide approximately 61 tables, 63 figures, and 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies